Monoclonal Antibodies Report Part II: Companies - Holding mAbs in portfolio promises protection against the looming 2011-12 patent cliff

This report provides a comprehensive strategic analysis of the mAb market out to 2012 by company. It identifies four 'established' and four 'emerging' players within the mAb sector which are forecast to play the most commercially significant role within this market. The report assesses how these players will be insulated from the impact of generic competition as a result of mAb market penetration.

Over the period 200612, monoclonal antibodies (mAbs) are forecast to act as the key growth segment of the prescription pharmaceutical market. mAb revenues are anticipated to grow at a compound annual growth rate of 14.2% over the period 200612, versus 2.2% for the overall market.

Four players currently hold a dominant position in the global mAb market: Genentech, Roche, Johnson & Johnson and Abbott, accounting for a combined 74.8% share of mAb market revenues.

However, Datamonitor forecasts that by 2012 a number of additional players will have significantly enhanced their presence in the mAb segment, with four companies: Biogen IDEC, Amgen, Novartis and UCB Pharmaeach forecast to generate mAb sales growth in excess of $1 billion.

Read more...

• The Top 10 Generic Pharmaceutical (14/10/2008)
• Monoclonal Antibodies Report (14/10/2008)
• Rx-to-OTC Strategies (10/10/2008)

• Biosimilars-Regulatory Issues (27/05/2008)
• Hematological Malignancies (21/05/2008)
• Biosimilars regulatory and development issues (20/05/2008)

• Acute Stroke (19/05/2008)
• Antifungals (16/05/2008)
• NNRTIs (16/05/2008)
• Non-Hodgkin's Lymphoma (16/05/2008)
• Multiple Myeloma (16/05/2008)
• Innovation in Drug Delivery (15/05/2008)
• Next-Generation Nutraceuticals (15/05/2008)
• Innovations in CNS (15/05/2008)
• Protein Engineering & Drug Design (14/05/2008)

---